Overview

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Status:
Completed

Trial end date:
2018-12-14

Target enrollment:

Participant gender:

Summary

The purpose of the study was to assess efficacy, tolerability, safety and pharmacokinetics of Romidepsin in subjects with progressive or relapsed peripheral T-cell lymphoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Romidepsin